Compound Profile
Wolverine Stack: BPC-157 and TB-500 Explained
Published: September 8, 2026
Updated: September 9, 2026
By the Curo Research Team
TL;DR
"Wolverine Stack" is a community nickname for pairing BPC-157 and TB-500, two research peptides with separate identities, separate manufacturing lots, and separate research records. BPC-157 is a synthetic 15-amino-acid fragment first isolated from human gastric juice; TB-500 in strict chemical terms is a 7-amino-acid fragment of thymosin beta-4, though vendors also use the name for the full 43-amino-acid protein. The two compounds are studied through different mechanisms and ship as two separate vials that are never pre-mixed, sold individually or as a set in the peptide catalog. As of July 2026, FDA's Pharmacy Compounding Advisory Committee reviewed both for the 503A Bulks List; neither is FDA-approved, and both remain on WADA's Prohibited List.
Where the "Wolverine Stack" name comes from
The nickname is fan culture layered onto lab chemistry. Ben Greenfield's peptide article series is the most commonly cited origin point for the "Wolverine Peptide Stack" label, and the framing stuck because both compounds get discussed for tissue-repair research, echoing the X-Men character's fictional healing factor. Dr. Neil Paulvin, DO, credits Greenfield with the coinage directly in his own clinical writing. None of this is a product name or a regulatory classification. It is a shorthand two compounds picked up because researchers keep studying them side by side, not because they arrive from a manufacturer as one substance.
That distinction matters for sourcing. Protocol literature commonly advises against combining the two peptides in one vial, because each has its own stability profile. Curo keeps them separate upstream: the BPC-157 + TB-500 set ships as two distinct vials, each carrying its own lot number and its own certificate of analysis, never pre-mixed into a single container.
What BPC-157 is
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide, sequence GEPPPGKPADDAGLV, with a molecular weight of 1,419.56 g/mol. Predrag Sikirić and colleagues at the University of Zagreb first described the parent gastric-juice protein in 1993, then characterized the synthetic 15-mer fragment the following year. The peptide has no approved trade name; "PL-10," "PL 14736," and the oral-tablet code "PCO-02" are development codes from its history at the Croatian pharmaceutical company Pliva. Research on BPC-157 spans rodent models of gastric protection, tendon and muscle repair, and angiogenesis, along with a small number of uncontrolled human pilot studies from a single US clinic. No published randomized controlled trial with results exists for BPC-157 in humans. You can read the full identity record, mechanism summary, and trial history in Curo's BPC-157 research record.
What TB-500 is, and why the name is contested
TB-500 is identity-sensitive in a way BPC-157 is not. In strict chemical usage, TB-500 refers to Ac-LKKTETQ, a 7-amino-acid acetylated fragment corresponding to residues 17-23 of thymosin beta-4. Many vendors and community sources instead use the "TB-500" label for full-length thymosin beta-4, a separate 43-amino-acid protein with its own molecular weight (about 4,963 g/mol) and its own development history, including ophthalmic and cardiac-repair research programs. A 2024 in vitro study found that the strict 7-amino-acid fragment did not itself enhance wound-healing activity, while a metabolite of that fragment did, which is one reason the identity distinction is not a technicality. Curo's TB-500 identity record walks through which registered trials track the 43-residue parent versus the shorter fragment, and why that split matters for reading the literature.
Why researchers study the pair together
The two compounds are studied through non-overlapping biology. BPC-157's best-characterized pathway drives angiogenesis through VEGFR2, Akt, and eNOS signaling, alongside FAK-paxillin activation in tendon fibroblast models. Thymosin beta-4's core described function is actin-binding and cytoskeletal remodeling, which researchers have connected to cell migration in cardiac and epithelial repair models. That non-overlapping profile, one compound acting on vascular signaling and fibroblast migration, the other on the cytoskeleton, is the mechanistic reason the pair appears together across community and practitioner protocols rather than either one alone.
Human evidence on the combination itself is close to nonexistent. The single published data point identified in the peer-reviewed literature is a subgroup of four patients within a 2021 retrospective knee-pain chart review, where three of four reported improvement after intra-articular BPC-157 combined with TB-500. That subgroup was not prespecified, carried no control arm, and involved four people. It is informational only, not evidence that the combination works in any general sense.
Two vials, two lots, two certificates
Because BPC-157 and TB-500 are separate molecules with separate synthesis runs, they arrive as separate products even when sold as a set. The combined set is built from Curo's standalone BPC-157 5 mg and TB-500 5 mg vials, each tested and lotted on its own. A certificate of analysis for a single-compound vial reports identity confirmation (typically mass spectrometry), purity by HPLC, and endotoxin testing for that one peptide against that one lot number. Reading two certificates side by side, rather than expecting one combined document, is part of verifying a Wolverine-stack order: the lot number printed on each vial should match the lot number on its certificate, and the two certificates should never be collapsed into one. See how Curo tests every lot for the three-method standard (HPLC, LC-MS, and endotoxin testing) applied to each individual peptide before a certificate is issued.
Regulatory status, current as of September 2026
Neither compound is FDA-approved for any human indication. On July 23-24, 2026, FDA's Pharmacy Compounding Advisory Committee (PCAC) met to evaluate whether several nominated bulk drug substances, including BPC-157-related substances (evaluated for ulcerative colitis) and TB-500-related substances (evaluated for wound healing), should be added to the Section 503A Bulks List. That meeting and its agenda are documented on FDA's own advisory-committee calendar. Legal reporting following the hearing indicated the committee voted 8-6, with one abstention, favoring inclusion of both the free-base and acetate forms of BPC-157 and of TB-500 on that list, while FDA's own staff had recommended against listing all seven substances under review. A favorable PCAC vote is advice to the agency, not agency action: it does not itself add a substance to the 503A Bulks List, does not constitute FDA approval, and does not establish that either peptide is safe or effective for any use. FDA has not announced a final decision as of this writing.
Both compounds are also restricted in competitive sport. BPC-157 has been on the World Anti-Doping Agency's Prohibited List since January 1, 2022, under Section S0 (Non-Approved Substances), banned at all times. The current 2026 Prohibited List, in force since January 1, 2026, names "Thymosin-beta4 and its derivatives e.g. TB-500" explicitly under Section S2.3, Growth Factors and Growth Factor Modulators, also banned at all times. Athletes subject to WADA-aligned testing, including USADA, NCAA, and major professional leagues, cannot use either compound in or out of competition. For how Curo documents its own lots against outside records, see is Curo legit: testing lots and independent records. Curo's full research-use posture is on the Research Use Only page.
Not the only pairing worth reading about
The Wolverine stack is one of several commonly discussed peptide combinations. A separate Curo article works through BPC-157 vs. TB-500: differences and when to combine in more mechanistic detail, and the same combination-literacy questions come up for other pairs, covered in CJC-1295 vs. Ipamorelin: differences and the blend and Semax vs. Selank: differences. All three start with identity and end with documentation, the same order this article follows.
FAQ
Is "Wolverine Stack" an official product name?
No. It is a community nickname, most commonly attributed to Ben Greenfield's peptide writing, for pairing BPC-157 and TB-500. Curo's product listing carries it as a recognizable label, not a regulatory or chemical designation.
Do BPC-157 and TB-500 ship pre-mixed in one vial?
No. They are two separate molecules, each with its own synthesis lot and its own certificate of analysis. Curo's set is built from two standalone vials, so each lot can be tested and documented on its own.
Are BPC-157 and TB-500 legal to buy?
Both are sold as research chemicals, labeled research-use-only, not for human or veterinary use. Neither is FDA-approved. As of July 2026, FDA's compounding advisory committee has reviewed both for a specific compounding pathway, but that review has not concluded in a final agency decision. Both remain on WADA's Prohibited List for competitive athletes. See Curo's Research Use Only policy and how to verify a certificate of analysis for what documentation to check before ordering.